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Abstract
Despite numerous efforts, drug based treatments for patients suffering from lung cancer remains poor. As a promising
alternative, we investigated the therapeutic potential of BC-819 for the treatment of lung cancer in mouse tumor models. BC-819
is a novel plasmid DNA which encodes for the A-fragment of Diphtheria toxin and has previously been shown to successfully
inhibit tumor growth in human clinical study of bladder carcinoma. In a first set of experiments, we examined in vitro efficacy of
BC-819 in human lung cancer cell-lines NCI-H460, NCI-H358 and A549, which revealed .90% reduction of cell growth. In vivo
efficacy was examined in an orthotopic mouse xenograft lung cancer model and in a lung metastasis model using luminescent
A549-C8-luc adenocarcinoma cells. These cells resulted in peri- and intra-bronchiolar tumors upon intrabronchial application and
parenchymal tumors upon intravenous injection, respectively. Mice suffering from these lung tumors were treated with BC-819,
complexed to branched polyethylenimine (PEI) and aerosolized to the mice once per week for a period of 10 weeks. Using this
regimen, growth of intrabronchially induced lung tumors was significantly inhibited (p=0.01), whereas no effect could be
observed in mice suffering from lung metastasis. In summary, we suggest that aerosolized PEI/BC-819 is capable of reducing
growth only in tumors arising from the luminal part of the airways and are therefore directly accessible for inhaled BC-819.
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Introduction
According to epidemiologic studies, lung cancer remains the
leading cause of cancer related deaths worldwide with only 15
percent of all patients in USA and 10 percent of all patients in
Europe surviving more than five years after diagnosis of the disease
[1]. This situation is mainly due to late diagnosis of lung tumors
and lack of therapeutic efficacy of currently available anticancer
drugs, especially in advanced stages of the disease when surgical
ablation is not feasible or tumors reoccur after surgery.
In order to close this therapeutic gap, gene therapy was sug-
gested as promising opportunity for interfering with critical
molecular pathways of cancer cells [2]. Recent strategies attempted
in clinical studies included induction of tumor cell apoptosis
through the replacement of mutated p53 tumor suppressor gene,
tumor cell suicide through induction of genes encoding for speci-
fic enzymes which are sensitive to otherwise benign agents and
activation of the immune system with genes encoding for cytokines
[3]. The majority of gene therapeutic approaches are based on viral
vectors which are highly efficient but due to development of
neutralizing antibodies, unfavorable for repeated application. Non-
viral vectors, though suitable for repeated application are relatively
less efficient, especially in the airways [4].
Due to safety issues, gene therapeutic agents are preferably
locally administered in current clinical trials. Indeed local
application of drugs has been shown to be advantageous in
various lung diseases, such as asthma, COPD and recently in lung
cancer [5]. In case of lung cancer for example, application of
chemotherapeutic drugs provided higher pulmonary drug levels
and additionally reduced systemic side effects [6]. Due to these
favorable distribution properties, aerosols have been considered
for the application of gene therapeutic agents. Plasmid DNA,
complexed with cationic polymers, resulted in successful transfec-
tion of bronchial and alveolar epithelium with reporter genes [7,8]
and reduced tumor growth when a therapeutic plasmid coding for
p53 was applied to lung tumor bearing mice [9].
Furthermore, it would be desirable to restrict the activity of the
applied plasmid DNA to the lung tumor cells only, thus leaving the
healthy tissue unaffected. In this context, plasmid BC-819 (also
known as DTA-H19) could be an ideal candidate. Plasmid BC-819
encodes the diphteria toxin A fragment under the control of the
H19-promoter. Expression of diphteria toxin A fragment inevita-
bly destroys cells by immediate disruption of protein synthesis and
the H19 promoter restricts its expression to tumor cells [10]. H19
is a paternally imprinted, maternally expressed, oncofetal gene
that has no protein product [11]. It is expressed at substantial
levels in several different human tumor types, but is only
marginally expressed or completely absent in normal adult tissues
[12]. Recent data suggested a role for H19 in promoting cancer
progression, angiogenesis and metastasis [13].
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effective in mouse models of lung cancer, we questioned whether
the localization of tumors may have an effect on the efficacy of the
tumor specific BC-819 plasmid. For this reason, plasmid BC-819
was applied as an aerosol in two groups of mice suffering from
lung tumors either induced by intrabronchial or intravenous
injection of human lung cancer cells. To qualify and quantify




Branched polyethylenimine (PEI, average molecular weight 25
kDa) was obtained from Sigma-Aldrich (Deisenhofen, Germany).
PEI was diluted in distilled water (water for injection, B. Braun
Melsungen AG, Melsungen, Germany) and adjusted to pH 7 with
HCl. D-Luciferin was obtained from Synchem (Felsberg/Alten-
burg, Germany).
Plasmids
The plasmids pCluc and pUC21 were obtained from Plasmid
Factory (Bielefeld, Germany). The plasmid pCluc codes for the
reporter enzyme luciferase derived from Photinus pyralis. The
plasmid pUC21 was used as negative control. The plasmid BC-
819 encodes for the A fragment of diphtheria toxin (DT-A) under
control of the H19 promotor and has already been described
elsewhere [10].
Cell lines
The cell line A549 was derived from a human lung tumor and
histologically classified as an adenocarcinoma [14]. The cell lines
NCI-H460 and NCI-H358 were isolated from human specimen
as well and histologically classified as large cell undifferentiated
carcinoma (NCI-H460) and bronchioloalveolar cell carcinoma
(NCI-H358). A549-C8-luc cells are A549 cells, stably transfected
with the gene coding for the reporter enzyme luciferase. All the
cell lines were obtained from DSMZ (German Collection of
Microorganisms and Cell Cultures, Braunschweig, Germany) ex-
cept for A549-C8-luc which was purchased from Caliper Life
Sciences (Alameda, California).
Animals
Due to disparities in the animals’ tumor susceptibility, different
mouse strains had to be used for the induction of primary and
secondary lung tumors, depending on the application route of the
tumor cells. T-cell deficient nude mice were described as good
donors for intrabronchially applied tumor cells recently [15] and
therefore chosen for the induction of primary lung tumors.
Successful generation of lung tumors through systemic adminis-
tration of tumor cells however was reported to require donor
animals with a high level of immune deficiency. For this reason T-,
B- and natural killer cell deficient CB17.Cg-Prkdc
scidLyst
bg-mice
were used for the secondary tumor model, just as described by
previous authors [16].
Prior to the experiments animals were acclimatized for at least 7
days. All further procedures were approved and controlled by the
local ethics committee (Regierung von Oberbayern) under the
approval number 16-08 and were conducted according to the
guidelines of the German law of protection of animal life.
Orthotopic tumor implantation procedure
Intrabronchial application. NMRI-Foxn1
nu mice were an-
esthetized through intraperitoneal injection of medetomidine
(11.5 mg/kg), midazolam (115 mg/kg) and fentanyl (1.15 mg/kg)
and subsequently placed on an angular board in order to visualize
the glottis using a light source, an otoscope and a modified spatula
(Hallowell, USA). 1610
6 A549-luc-C8 cells diluted in 100 ml PBS
were applied orotracheally with a blunt ended, bended 27 G
stainless steel needle which was adapted to a 1 ml Injekt-F plastic
Figure 2. Bioluminescence imaging of lung tumors. Growth of
orthotopic lung tumors was measured at defined time-points using
bioluminescence imaging. Intrabronchially induced tumors (A) ap-
peared initially in the jugular region and disseminated to the deeper
lungs at later time points, whereas intravenously induced tumors (B)
were restricted to the lung region only.
doi:10.1371/journal.pone.0020760.g002
Figure 1. Effect of BC-819 on cell growth in different lung cancer cell lines. NCI-H460, NCI-H358 and A549 cells were transfected, using
Lipofectamine 2000, with BC-819 and co-transfected with a plasmid, encoding for the reporter enzyme luciferase. As early as 24 h after transfection,
luciferase activity (indirectly indicating cell growth) was reduced by at least .90% when 350 ng BC-819 was used (A). 48 hours later luciferase activity
was decreased by more than 98%, except for the cell line NCI-H358. However, a luciferase decrease of more than 98% was observed in all cell lines
when the amount of BC-819 was increased to 700 ng (B). The influence of BC-819 on bioluminescent A549-C8-luc was examined as well and revealed
decreased luciferase and therefore reduced cell growth (more than 50%) as early as after 24 hours (C). Maximum inhibition of cell growth was
reached by 48 hours after transfection, becoming apparent through more than 75% reduction in luciferase activity.
doi:10.1371/journal.pone.0020760.g001
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sequent to the implantation procedure, anesthesia was antago-
nized through the subcutaneous injection of an antidote consisting
of atipamezol (50 mg/kg), flumazenil (10 mg/kg) and naloxon
(24 mg/kg). Mice recovered from anesthesia within 15 min.
Intravenous application. Conscious CB17.Cg-Prkdc
scidLyst
bg-
mice were placed in a mouse-restrainer (Braintree Scientific Inc,
USA) and 1610
6 A549-C8-luc cells diluted in 100 mlP B Sw e r e
injected directly into the dorsal tail-vein using a 29G U-100 Insulin
syringe (BD Consumer Healthcare, Le Pont de Claix, France).
In vivo imaging
Animals were anesthetized just as described before. D-luciferin
substrate (3 mg/100 ml PBS per mouse) was applied by intraper-
itoneal injection in the group of mice suffering from lung tumors
which were provoked by intravenous injection of A549-C8-
luc cells. Mice suffering from tumors which were induced by
intrabronchial application of A549-C8-luc received the same
amount of D-Luciferin diluted in 50 ml PBS via the intranasal
route [17]. Bioluminescence was measured 10 minutes later, using
an IVIS 100 Imaging System (Xenogen, Alameda, USA) and the
camera settings: field of view 10, f1 f-stop, high-resolution binning
and exposure-time of 5 min. The signal was quantified and
analyzed using the Living Image Software version 2.50 (Xenogen,
Alameda, USA).
Preparation of PEI-pDNA polyplexes
Branched polyethylenimine (PEI; average MW=25 kDa) was
obtained from Sigma-Aldrich (Deisenhofen, Germany), dissolved
in water, and adjusted to pH 7 using HCl. Polyplexes for aerosol
application were formulated as previously described [7]. Briefly:
BC-819 plasmid and branched PEI were separately diluted
in distilled water to 4 ml, resulting in concentrations of 0.25
mg/ml BC-819 and 0.33 mg/ml branched PEI, respectively
(corresponding to a N/P ratio of 10). The pDNA solution was
pipetted into the PEI solution and mixed by pipetting up and
down to yield a final pDNA concentration of 0.125 mg/ml. The
complexes were incubated for 20 min at ambient temperature
before use.
Aerosol application of PEI-pDNA polyplexes
Aerosol application was performed as described previously [18].
Briefly, a LC STAR Nebulizer (Pari, Starnberg, Germany), driven
by high pressure, which was generated from a BOYHSX
compressor (Pari, Starnberg, Germany) was connected to a spacer,
filled with 500 g Drying pearls Orange (Sigma-Aldrich, Deisen-
hofen, Germany). The spacer in turn was connected to a plastic
box with four small holes at the opposite side, in order to allow
aerosol flow. In order to facilitate higher aerosol deposition in the
lung, animals were encouraged for accelerated breathing by
driving the compressor with synthetic air, enriched with 5% CO2.
Histology
Animals were euthanized by intraperitoneal injection of
pentobarbital. Subsequently the lungs were removed, inflated
with 4% paraformaldehyde through the trachea and further pro-
cessed for Haematoxylin-Eosin staining according to a standard
protocol.
In-situ hybridization
In-situ hybridization (ISH) was performed as described by Ariel
et al [16], using the digoxigenin labelled H19 RNA probe or by a
modification of this method using H19-LNA (locked nucleic acid)
Dig-labelled probe synthesized at Exiqon.
Statistics
Results are reported as means and standard deviations.
Statistical significance between two groups was determined with
a Mann-Whitney-U-Test for in-vitro results and with a Logrank-test
for in-vivo results. Probability (P),0.05 was considered significant.
Figure 3. Histology of orthotopically induced lung tumors. Tumors were detectable as early as 10 days after intrabronchial implantation in the
peribronchiolar region of the lungs (A). End stages of intrabronchially induced lung tumors were characterized by multiple, peribronchiolar and parenchymal
localized tumors (B) and by tumor tissue within the luminal lung regions as well (C). Intravenous injection of A549-C8-luc, however, resulted in tumors
predominately growing in the parenchyma of the lungs but not peribronchiolar or within the bronchi (D). Figure D showsparenchymal tumor tissue close to
a bronchus, but not peribronchiolar. Alveolar tissue localized between the tumor and the bronchus however is condensed by the adjacent tumor nodule.
doi:10.1371/journal.pone.0020760.g003
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Results
Plasmid pBC-819 inhibits in vitro cell proliferation of
human lung cancer cells
In vitro transfection experiments were conducted in different
human lung cancer derived cell-lines. Increasing amounts of pBC-
819 (0, 350 and 700 ng) were co-transfected with 100 ng of
luciferase encoding plasmid. The total amount of pDNA was filled
up to 800 ng for all the compared samples using pUC21 plasmid
as filler pDNA. Hence, the efficacy of pBC-819 was indirectly
determined by a reduction of luciferase activity, indicating de-
struction of transfected tumor cells.
Using Lipofectamine 2000 as transfection reagent, a time and
dose dependent decline of luciferase activity was observed in each
of the cell lines used. The effect of pBC-819 became apparent as
early as 24 hours after transfection with a reduction in luciferase
activity of more than 90% when 350 ng (Fig. 1A) and more than
95% (Fig. 1B) when 700 ng of BC-819 were used. More than 98%
of the luciferase activity was inhibited 48 hours after transfection
when 700 ng BC-819 were used. Similar result was also obtained
with 350 ng, except for the cell line NCI-H358.
These studies inspired us to screen this plasmid with the cell line
A549-C8-luc, which had been stably transfected with luciferase.
Measurement of luciferase at different time points post transfection
showed that BC-819 was effective in A549-C8-luc cells as early as
24 hours after transfection (Fig. 1C). The lower concentration
(400 ng) of BC-819 showed to be capable of reducing luciferase
activity by more than 50%. Using 800 ng BC-819, it was possible
to decrease the luciferase activity by more than 75%. Taken
together these studies revealed a clear effect of plasmid BC-819 on
cell viability of human lung cancer cells in vitro.
Growth of lung tumors depends on the application site
of tumor cells
To evaluate the efficiency of pBC-819 aerosol therapy in vivo,
orthotopic lung tumors were generated in immune deficient mice
by intrabronchial or intravenous application of A549-C8-luc cells.
We found that the choice of the application route largely affected
the growth patterns of the resulting lung tumors and influenced
animal survival. Intrabronchial application of A549-C8-luc cells
gave rise to luminescent tumors, initially localized in the jugular
region, by 10 days post transplantation and then disseminating
caudally to the left or right lung within 66 days (Fig. 2A). However,
tumors which were induced through intravenous injection of
A549-C8-luc tumor cells, were characterized by disseminated
bioluminescence signals in both lungs after 10 days which then
continuously increased (Fig. 2B).
Histopathological post mortem examination of intrabronchially
induced lung tumors revealed first evidence of tumor tissue within
the peribronchiolar region after 10 days (Fig. 3A). Examinations at
later time points revealed multiple tumor nodules, localized in the
parenchyma, the peribronchiolar region and within the bronchia
(Fig. 3 B–C). Lungs, affected from intravenously induced tumors,
however, were characterized by disseminated tumor tissue only in
the parenchyma of the organ (Fig. 3 D).
A549-C8-luc based lung tumors are strongly positive for
the H19 oncogene
Because the presence of the non-coding RNA H19 is crucial for
the efficacy of BC-819, we examined tumor tissue for the presence
of non-coding H19 RNA. In-situ-hybridization revealed a strong
expression of H19 in A549-C8-luc based lung tumors, indicated by
brownish colorization of the examined tissue (Fig. 4).
Inhalation of PEI/pBC-819 aerosol inhibits primary but
not secondary tumor growth
Based on the results from in vitro experiments,the efficacy ofpBC-
819 was investigated in vivo through the application of aerosolized
pBC-819 plasmid to lung tumor bearing mice. These experiments
were conducted in mice suffering from either intrabronchially or
intravenously induced lung tumors in order to mimic pBC-819’s
impact on primary and secondary lung tumors.
For subsequent aerosol application pBC-819 was complexed
to branched PEI and administered in a modified whole-body
inhalation chamber. Treatment of lung tumor bearing mice was
started at 21 days after tumor cell transplantation, as soon as the
evidence of lung tumors had been verified using in vivo bio-
luminescent imaging. The treatment protocol included one inha-
lation procedure a week for a total time period of 10 weeks.
These experimentsrevealedeithercompletely abolishedorseverly
attenuated tumor progression in mice suffering from intrabronchi-
ally induced lung tumors when treated with PEI/pBC-819 aerosol
(Fig. 5A–B). A bioluminescenceactivity ofmorethan2610
5 photons
Figure 4. In-situ-hybridization for H19-activity in lung tumors.
An intrabronchially induced lung tumor was stained for H.E. (A) and
screened for H19-activity using ISH (B). In the given sample a strong
expression of H19 was found, indicated by a brownish colorization of
the examined tissue.
doi:10.1371/journal.pone.0020760.g004
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general condition (indicated by rapid weight loss and dyspnea) and
therefore defined as endpoint-criteria. Based on this procedural
method, a median survival of 66 days was calculated for animals
of the untreated control group. In contrast to this, treated mice
survived more than 200 days, even though aerosol application of
PEI/pBC-819 aerosol was terminated more than 100 days earlier,
on day 91. Except for one mouse, all treated mice (n=5) survived
more than 200 days, being either free of lung tumors or showing
reduction of tumor growth and no impairment of the general
condition. One mouse had no signs of tumor evidence in the lungs
on day 200, but indeed one distant metastasis in the brain (data not
shown).
Finally, day 200 was elected to be the endpoint of the study.
Statistical analysis of the results revealed a highly statistically
significant difference (p=0.01) between treatment and control
group regarding the time which was necessary to reach the end-
point of the study (Fig. 6A).
Treatment with PEI/pBC-819-aerosol showed to be less ef-
ficient in mice suffering from lung tumors, which were generated
through the intravenous injection of A549-C8-luc tumor cells. As
mentioned before, tumor cells entered the lungs through blood
circulation, consequently influencing localization and growth
patterns of the lung tumors, resulting in tumors growing in the
parenchyma, but not in the bronchi. Under this condition,
treatment with PEI/pBC-819-aerosol resulted in no statistically
significant difference between treated and untreated animals.
Even though intravenously induced tumors grew more rapidly,
impairment of the general condition was recognized as soon as
a luciferase activity exceeded 1610
6 photons per second, which
was therefore chosen as an endpoint for mice suffering from
intravenously induced lung tumors. The median time to reach this
endpoint was 43 days for the untreated animals and 36 days for
the treated animals. Furthermore statistical analysis of these results
revealed no significant difference (p=0.3) between treated and
untreated mice (Fig. 6B).
In summary, the results of these experiments demonstrate, that
aerosolized PEI/pBC-819 is capable of inhibiting lung tumor
growth in mice suffering from intrabronchially induced lung
tumors. Moreover, the present results show that a comparable
effect could not be observed in mice, which suffered from par-
enchymal lung tumors, after intravenous application of tumor
cells.
Discussion
Gene therapy is considered to facilitate treatment opportunities
for incurable pulmonary diseases including monogenetic defects
like cystic fibrosis, alpha1-antitrypsin deficiency and complex
disease like asthma and lung cancer [19]. In this regard, local
application of gene therapeutic drugs as aerosols has been
considered to be advantageous for targeting of the lungs because
Figure 5. BLI of untreated and treated tumor-bearing mice at different time points. Growth of lung tumors in untreated mice was
characterized by initial tumor appearance in the neck region and subsequently continuous dissemination into the lungs (A). This growth pattern
differed in mice which were treated with BC-819 where tumors either decreased in size or in completely vanished during treatment.
doi:10.1371/journal.pone.0020760.g005
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directly at the site of disease and ii) severe side effects which could
be provoked by systemic application of nucleic acids and/or gene
therapeutic vectors would be minimized. The concept of aerosol
based gene therapy was further investigated in the present work
through the application of the plasmid BC-819 in an orthotopic
xenograft model of human lung cancer. In this regard, we
investigated if tumor cell specific plasmids were capable of
destroying only primary tumors of the luminal airways or if they
were also capable of showing an effect against secondary tumors
located in the parenchymal tissue. To address this question, lung
tumors were induced using two different application routes of lung
cancer cells. Tumors growing from the luminal side of the lungs
were obtained when cells were applied intrabronchially and
tumors growing from the blood vessels’ side were obtained by
applying the cells intravenously. Histology of intrabronchially
Figure 6. Survival of untreated and treated tumor-bearing mice. Mice bearing intrabronchially induced lung tumors showed a significant
survival benefit (p=0.01) when treated with BC-819 compared to animals which received no treatment (A). No survival benefit was observed in mice
suffering from intravenously induced lung tumors, independent of treatment with BC-819 (B).
doi:10.1371/journal.pone.0020760.g006
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the organ and in the bronchial walls. These findings correspond
with results, which were reported by other authors [15].
Intravenous injection of tumor cells, however, resulted in car-
cinomas only growing in the parenchyma of the lungs but not in
the bronchial walls. Tumor growth monitoring using biolumines-
cent imaging furthered the results achieved from histology,
revealing different growth patterns of tumors, which were induced
intrabronchially and intravenously. Interestingly, we found that
intrabronchially induced lung tumors arise from the peribronchi-
olar region which suggests that intrabronchially applied cells must
be capable to invade and conquer the bronchial epithelia in order
to colonize the peribronchiolar tissue. This finding is encouraging
with respect to the results of other groups who demonstrated
colonization of lung epithelia with labeled genetically engineered
mesenchymal stem cells when applied through the intrabronchial
route [20]. Based on the presumption that intrabronchially applied
tumor cells initially invade the epithelial layers in the bronchial
region to subsequently spread peribronchiolar, we suggested that
treatment with aerosolized BC-819 should be efficient in de-
stroying the tumor cells as we and others have previously shown
that nebulized luciferase encoding plasmid DNA predominately
transfects the bronchial and alveolar epithelia when complexed to
branched PEI [7][8].
In order to substantiate our assumption, we treated tumor-
bearing mice with the plasmid BC-819 which has recently been
shown to be therapeutically efficient in BCG-resistant bladder
carcinomas in patients [21]. Plasmid BC-819 codes for the A
fragment of diphtheria toxin and is driven by the H19 promotor.
As H19 promoter is active only in malignant cells and during
embryogenesis, tumor tissue is destroyed, while healthy tissue stays
unharmed [10]. Prior to in vivo experiments the efficacy of BC-819
was determined in the lung cancer cell lines NCI-H460, NCI-
H358 and A549 in vitro, revealing a considerably inhibiting effect
on cell growth. It has been previously shown that the non-coding
H19 mRNA is highly expressed, indicating active H19 promoter,
in lung cancer cell lines, especially in A549 [22]. Consequently,
lung cancers in mice were induced using the luciferase expressing
cell line A549-C8-luc which had also been shown to be susceptible
for the plasmid BC-819. Furthermore, the lungs were examined
post mortem for H19-expression by In-situ-hybridization which
revealed strong evidence of H19 expression in A549-C8-luc lung
tumors.
This experiment revealed that weekly aerosol treatment with
PEI/BC-819 gives a significant (p=0.01) survival benefit for mice
suffering from intrabronchially induced lung tumors but not to
mice suffering from intravenously induced lung tumors (p=0.36).
Based on these results, we speculate that PEI/BC-819 aerosol
treatment is only effective in primary lung tumors which are
accessible through inhalation because the malignant growth pre-
dominately arises from the luminal part of the airways. In contrast
to this, tumor growth of intravenously induced lung tumors
primarily evolves from the blood vessels, subsequently invading the
parenchyma of the lung. As mentioned before, aerosol based gene
transfer is predominantly restricted to the bronchial epithelia.
Certainly this does not mean that therapeutic effects could not be
achieved for the entire organ. In fact several studies successfully
demonstrated effects of nebulized pDNA in secondary models of
lung cancer [23]. However, other plasmid constructs were used in
these studies, without cancer cell specific promoters and including
genes for less cell toxic proteins, e.g. the tumor suppressor protein
p53. Furthermore, an apoptotic protein such as p53 will most
likely not lead to immediate destruction of the transfected cell,
therefore raising the possibility that excessive p53 could be
released from the transfected cell or more likely, paracrine or
interleukin mediated signaling could be activated in the surround-
ing tissue.
Even though aerosol application seems promising for future
treatments of severe lung diseases, it should be kept in mind that
this kind of therapy also seems much like a tightrope walk. Indeed,
the likelihood of severe side effects, such as inflammation or
allergic reactions, will increase with the toxicity and irritability of
the applied substances, which consequently limits the advantage
of the inhalation route. Concerns like these may have been
considered in particular for the aerosol application of cytotoxic
substances such as paclitaxel [6] or doxorubicin [5] but may also
be relevant for the application of nucleic acids. Indeed a potent
immune system not only acts on foreign pathogens but also on
non-viral vectors and nucleic acids. However, only a slight increase
of cytokines has been described for the aerosol application of
branched PEI to the lungs [24,25,26]. Besides inflammation due to
immune reactions, severe side effects could evolve from destroyed
tissue. In this regard the particular architecture of the lungs should
be considered. The high incidence of blood vessels raises the
susceptibility for life threatening lung bleedings (hemoptysis),
which could be induced by cell toxic substances [27]. Under this
consideration it seems likely that tumor cell specific plasmids such
as BC-819 which only destroys tumor but not healthy tissue could
bring promising benefits for the aerosol treatment of lung cancers.
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